Butorphanol市场按给药途径、用途、最终用户和分销管道划分－2025-2032年全球预测

预计到 2032 年，Butorphanol市场规模将成长至 4.0017 亿美元，复合年增长率为 4.39%。

本文简要概述了Butorphanol的药理作用和处方注意事项，重点介绍了其在现代疼痛管理策略中的地位。

Butorphanol作为一种混合型鸦片受体促效剂/拮抗剂，在镇痛药物治疗中占据独特的地位，临床上常用于治疗急性中重度疼痛。其动态特性结合了κ阿片受体激动作用和部分μ阿片受体拮抗作用，与完全μ受体促效剂相比，在疗效和安全性之间取得了独特的平衡。临床医师在权衡镇痛效果与呼吸抑制及其他μ受体介导的副作用时，尤其在分娩和围手术全期护理等情况下，会格外重视布托啡诺的这些特性。

监管重点、供应链现代化和以患者为中心的护理模式正在融合，重新定义疼痛药物的临床和商业性方法。

包括Butorphanol在内的镇痛​​药物市场正经历着变革性的转变，其驱动力包括监管力度的加大、以患者为中心的护理模式的推行以及供应链的现代化。对鸦片类药物管理和替代疼痛途径的日益重视正在加速联合治疗的普及，而具有混合促效剂-拮抗剂特性的药物正被重新评估其在特定适应症中的应用。同时，临床上对肠外给药方式的需求不断增长，促使临床医生和采购团队重新评估注射剂和鼻腔製剂的处方笺分配，这些製剂能够在住院和门诊环境中提供快速、可滴定的镇痛效果。

评估截至2025年的最新关税政策调整如何重塑止痛药价值链的筹资策略、供应弹性措施和采购决策。

美国关税的实施和调整将持续到2025年，这对Butorphanol相关医药价值链造成了多方面的压力。关税导致进口原料药和特殊辅料成本增加，使采购流程更加复杂，并可能促使生产商重新评估其筹资策略。为此，一些生产商正在寻求供应来源多元化、进行合约避险，并与国内契约製造组织（CMO）合作，以降低进口关税和物流中断的风险。

以细分市场为重点，整合给药途径、治疗用途、终端使用者需求和分销管道，得出可操作的临床和商业性见解。

细分市场分析揭示了Butorphanol在临床应用、采购途径和患者获取方面的显着模式。根据给药途径，相关人员会评估注射剂、鼻腔製剂和口服製剂。注射途径进一步细分为肌肉注射和静脉注射，每种途径都针对特定的临床工作流程，例如手术全期和急诊情况下的快速剂量调整。根据适应症，布托啡诺在慢性疼痛管理、分娩疼痛和手术疼痛方面的治疗定位有所不同，需要製定个人化的临床通讯协定并对处方医生进行培训，以确保最佳的治疗效果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 慢性疼痛管理中缓释性Butorphanol製剂的应用日益广泛
• 非专利的竞争威胁着品牌Butorphanol注射的价格和利润率。
• 对阿片类止痛药审批途径的监管审查力道加大，影响了Butorphanol的核准时间表。
• 急诊室越来越倾向于使用鼻Butorphanol给药，因为它起效更快。
• 一项真实世界证据研究旨在证Butorphanol製剂的相对疗效
• 对成本控制措施的日益重视正在推动对Butorphanol在多重止痛通讯协定中的评估。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Butorphanol市场及给药途径

• 注射
  • 肌肉内注射
  • 静脉注射
• 鼻喷剂
• 药片

第九章Butorphanol市场依应用领域划分

• 慢性疼痛管理
• 分娩疼痛管理
• 手术疼痛管理

第十章Butorphanol市场（以最终用户划分）

• 门诊治疗中心
• 家庭医疗保健
• 医院

第十一章Butorphanol市场依通路划分

• 医院药房
• 网路药房
• 零售药房

第十二章 各地区Butorphanol市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章Butorphanol市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国Butorphanol因市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Mylan NV
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Sagent Pharmaceuticals, Inc.
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • Apotex Inc.

The Butorphanol Market is projected to grow by USD 400.17 million at a CAGR of 4.39% by 2032.

A concise clinical framing of butorphanol's pharmacological role and prescribing considerations that illuminate its place in contemporary analgesic strategies

Butorphanol occupies a distinct niche within analgesic pharmacotherapy as a mixed opioid agonist-antagonist that is frequently employed for acute moderate to severe pain management in clinical settings. Its pharmacodynamic profile, which combines kappa-opioid receptor agonism with partial mu-opioid receptor antagonism, gives it unique efficacy and safety trade-offs compared with full mu agonists. Clinicians value these characteristics when balancing analgesia against respiratory depression and other mu-mediated adverse effects, particularly in settings such as labor and perioperative care.

Clinical practice and formulary committees evaluate butorphanol through multiple lenses: route of administration flexibility, rapid onset in injectable forms, the convenience of intranasal delivery in outpatient and ambulatory contexts, and tolerability in diverse patient populations. Regulatory pathways and hospital protocols influence how healthcare providers integrate butorphanol into multimodal analgesia strategies, while pharmacovigilance continues to refine risk mitigation for opioid-related events. Amid evolving pain management paradigms and heightened scrutiny of opioid prescribing, butorphanol's pharmacological attributes sustain its role in targeted therapeutic scenarios.

How regulatory focus, supply chain modernization, and patient-centric care models are converging to redefine clinical and commercial approaches to analgesics

The landscape for analgesics, including butorphanol, is undergoing transformative shifts driven by regulatory scrutiny, patient-centric care models, and supply chain modernization. Increasing emphasis on opioid stewardship and alternative pain pathways has accelerated adoption of multimodal regimens where agents with mixed agonist-antagonist profiles are reconsidered for specific indications. Concurrently, clinical demand for non-oral delivery has grown, prompting clinicians and procurement teams to reassess formulary placement for injectable and intranasal therapies that permit rapid, titratable analgesia in both inpatient and outpatient settings.

Supply chain dynamics are also changing; manufacturers and healthcare systems are investing in redundancy, nearshoring of critical intermediates, and tighter quality controls to safeguard continuity. These shifts are complemented by digital health innovations that enable remote patient monitoring and telehealth-facilitated prescribing, which influence the roles of ambulatory care centers, home healthcare providers, and hospital systems in delivering analgesic therapy. Taken together, these forces are reshaping how butorphanol is positioned clinically and commercially, creating opportunities for differentiated formulations and targeted educational outreach to prescribers.

Assessment of how recent tariff policy adjustments through 2025 have reshaped sourcing strategies, supply resilience efforts, and procurement decision-making across the analgesic value chain

The imposition and recalibration of tariffs in the United States through 2025 have exerted multi-dimensional pressure on the pharmaceutical value chain relevant to butorphanol. Tariff-driven increases in the cost of imported active pharmaceutical ingredients and specialty excipients can amplify procurement complexity and incentivize manufacturers to reassess sourcing strategies. In response, some producers have pursued supplier diversification, contractual hedging, and partnerships with domestic contract manufacturing organizations to lessen vulnerability to import levies and logistical disruption.

These adjustments have downstream implications for formulary committees and healthcare purchasers who must reconcile pricing dynamics with commitments to uninterrupted clinical supply. At the same time, tariff changes intersect with regulatory and quality assurance priorities; organizations that accelerate localization of critical manufacturing steps often face initial capital and compliance investments that lengthen lead times but strengthen long-term resilience. As a result, strategic players emphasize supply transparency, batch-level traceability, and collaborative forecasting to mitigate the operational impacts of tariff policy shifts while maintaining stewardship of therapeutic availability.

Segment-focused clinical and commercial implications that align administration routes, therapeutic applications, end-user needs, and distribution channels into actionable insights

Insight into segmentation reveals meaningful patterns in clinical use, procurement pathways, and patient access for butorphanol. Based on route of administration, stakeholders evaluate injectable options versus intranasal delivery and oral formulations; the injection pathway is further differentiated by intramuscular and intravenous modalities, each aligned to specific clinical workflows such as rapid titration in perioperative or emergency settings. Based on application, therapeutic positioning varies across chronic pain management, labor pain, and surgical pain, prompting tailored clinical protocols and education for prescribers to ensure optimal outcomes.

Based on end user, adoption and utilization differ among ambulatory care centers, home healthcare services, and hospitals, with each setting presenting distinct procurement cycles, storage requirements, and administration competencies. Based on distribution channel, supply continuity is managed through hospital pharmacies, online pharmacies, and retail pharmacies, which collectively shape patient access and the logistics of replenishment. Integrating these segmentation lenses helps stakeholders align development priorities, clinical education, and commercial outreach to the settings and administration routes where butorphanol demonstrates the strongest clinical fit.

Regional dynamics shaping regulatory pathways, clinical adoption, and supply chain design across the Americas, EMEA, and Asia-Pacific for analgesic therapies

Regional dynamics exert a pronounced influence on regulatory frameworks, clinical practice patterns, and supply chain architecture for butorphanol. In the Americas, policy debates around opioid stewardship and robust hospital-based acute care networks drive concentrated use in perioperative and labor contexts, while procurement strategies increasingly emphasize supply continuity and compliance with evolving controlled-substance regulations. Manufacturers and distributors in this region calibrate educational outreach and formulary support to reflect these institutional priorities and rigorous regulatory oversight.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and diverse healthcare infrastructures create differentiated adoption pathways; some jurisdictions prioritize community-based pain management and outpatient access, whereas others rely heavily on centralized hospital procurement and strict narcotics controls. These variations necessitate nuanced regulatory submissions and localized pharmacovigilance frameworks. In the Asia-Pacific region, rapid expansion of ambulatory care, growing home healthcare delivery models, and investments in localized manufacturing capacity shape demand dynamics, with regional players increasingly focused on scalability, cost-efficiency, and alignment with public health guidelines. Collectively, these regional currents inform market entry strategies, distribution partnerships, and clinical engagement models.

Competitive positioning and strategic collaboration themes among manufacturers, specialty firms, and contract partners that determine supply reliability and clinical uptake

Competitive and collaborative forces among manufacturers, specialty pharmaceutical firms, and contract development and manufacturing organizations are central to how butorphanol is developed, produced, and distributed. Large generic manufacturers leverage scale and integrated supply chains to support steady production and broad distribution, whereas specialty companies focus on formulation innovation, niche indications, and provider education to differentiate products. Contract manufacturers and CDMOs play an increasingly strategic role by enabling capacity expansion, compliance with evolving good manufacturing practices, and rapid technology transfer for localized production.

Strategic collaborations between commercial teams and clinical educators drive adoption in targeted settings, while supply chain partnerships emphasize redundancy and regulatory alignment. Companies are also investing in pharmacovigilance infrastructure, real-world evidence generation, and lifecycle management to sustain product relevance amid heightened scrutiny of opioid therapies. Taken together, these dynamics highlight the importance of operational excellence, clinical engagement, and adaptive commercial models for stakeholders involved in the butorphanol value chain.

Practical strategic measures that industry leaders can implement to fortify supply resilience, clinical adoption, and channel alignment for analgesic products

Industry leaders can take several practical, actionable steps to strengthen clinical adoption, supply resilience, and commercial performance in the evolving analgesic environment. First, prioritize targeted clinical education and institution-level stakeholder engagement that highlights where mixed agonist-antagonist agents can offer clinical advantages and how they fit within multimodal pain protocols. Second, accelerate supplier diversification and consider nearshoring key manufacturing steps to reduce exposure to import tariffs and logistics shocks while investing in compliance and quality systems to maintain regulatory alignment.

Third, tailor distribution strategies to the operational realities of ambulatory care centers, home healthcare providers, and hospitals by optimizing channel partnerships with hospital pharmacies, online dispensaries, and retail outlets to preserve access. Fourth, invest in pharmacovigilance and real-world evidence programs that substantiate safety and efficacy profiles in the settings most relevant to product use, thereby facilitating informed formulary decisions. Finally, leverage collaborative contracting and shared-risk procurement models with healthcare systems to build long-term partnerships focused on continuity of supply, cost predictability, and clinical outcomes.

A transparent and ethically grounded research methodology combining expert interviews, regulatory review, and data triangulation to validate clinical and supply insights

This research synthesizes primary and secondary information streams, including structured interviews with clinical experts, procurement officers, and manufacturing executives to validate operational realities and clinical nuances. Secondary research incorporated regulatory filings, peer-reviewed clinical literature, pharmacovigilance reports, and public policy announcements to contextualize practice patterns and policy impacts. Data triangulation ensured that qualitative insights from expert discussions were cross-checked against documented regulatory updates, clinical guidance, and observable supply chain developments.

Methodological rigor was maintained through transparent inclusion criteria for expert selection, standardized interview guides, and a replicable approach to synthesizing disparate evidence. Limitations are acknowledged where public data is sparse or where practice variability across jurisdictions limits generalizability; consequently, recommendations emphasize strategic flexibility and the need for localized validation. Ethical standards governed interactions with clinical informants, and proprietary data sources were treated under non-disclosure protocols to protect commercial sensitivity while preserving analytical integrity.

A conclusive synthesis emphasizing how clinical positioning, supply resilience, and evidence strategies together determine the future role of analgesic options in care delivery

In conclusion, butorphanol remains a clinically relevant analgesic option whose utility is shaped by its pharmacological profile, administration routes, and the settings in which pain management decisions are made. The confluence of regulatory scrutiny, shifting clinical paradigms toward multimodal analgesia, and changes in trade policy through 2025 underscores the need for adaptive sourcing, targeted clinical engagement, and rigorous safety monitoring. Stakeholders that integrate these imperatives into procurement, formulation strategy, and clinician outreach will be better positioned to sustain access and demonstrate therapeutic value.

Looking forward, success will favor organizations that combine operational resilience with nuanced clinical messaging and evidence generation. Emphasis on partnership models with healthcare systems, investments in localized manufacturing capabilities where feasible, and proactive pharmacovigilance will help balance stewardship objectives with patient access. Ultimately, a measured, evidence-based approach to product positioning and supply strategy will maximize the ability to meet clinical needs while navigating an increasingly complex regulatory and commercial landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Increased adoption of extended-release butorphanol formulations for chronic pain management
• 5.2. Emergence of generic competitors challenging branded butorphanol injection pricing and margins
• 5.3. Regulatory scrutiny intensifying on opioid analgesic pathways impacting butorphanol approval timelines
• 5.4. Growing preference for intranasal butorphanol delivery in emergency departments to reduce onset time
• 5.5. Integration of real-world evidence studies to demonstrate comparative effectiveness of butorphanol formulations
• 5.6. Rising emphasis on cost containment initiatives driving evaluation of butorphanol in multimodal analgesia protocols

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Butorphanol Market, by Route Of Administration

• 8.1. Injection
  • 8.1.1. Intramuscular Injection
  • 8.1.2. Intravenous Injection
• 8.2. Nasal Spray
• 8.3. Tablet

9. Butorphanol Market, by Application

• 9.1. Chronic Pain Management
• 9.2. Labor Pain Management
• 9.3. Surgical Pain Management

10. Butorphanol Market, by End User

• 10.1. Ambulatory Care Center
• 10.2. Home Healthcare
• 10.3. Hospital

11. Butorphanol Market, by Distribution Channel

• 11.1. Hospital Pharmacy
• 11.2. Online Pharmacy
• 11.3. Retail Pharmacy

12. Butorphanol Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Butorphanol Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Butorphanol Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Teva Pharmaceutical Industries Ltd.
  • 15.3.2. Sandoz International GmbH
  • 15.3.3. Pfizer Inc.
  • 15.3.4. Mylan N.V.
  • 15.3.5. Fresenius Kabi AG
  • 15.3.6. Hikma Pharmaceuticals PLC
  • 15.3.7. Sagent Pharmaceuticals, Inc.
  • 15.3.8. Baxter International Inc.
  • 15.3.9. B. Braun Melsungen AG
  • 15.3.10. Apotex Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BUTORPHANOL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS BUTORPHANOL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL BUTORPHANOL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL BUTORPHANOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BUTORPHANOL MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. BUTORPHANOL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BUTORPHANOL MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BUTORPHANOL MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BUTORPHANOL MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BUTORPHANOL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BUTORPHANOL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. AMERICAS BUTORPHANOL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS BUTORPHANOL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 103. AMERICAS BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 105. AMERICAS BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 107. AMERICAS BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 108. AMERICAS BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 109. AMERICAS BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 110. AMERICAS BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 111. AMERICAS BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 112. AMERICAS BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 113. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 116. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 117. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 118. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 119. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 120. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 121. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 122. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 123. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 124. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 125. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 128. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 129. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 130. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 131. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 132. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 133. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 134. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 135. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 136. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 138. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 139. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 141. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 142. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 143. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 144. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 145. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 149. EUROPE BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. EUROPE BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. EUROPE BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 152. EUROPE BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 153. EUROPE BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 154. EUROPE BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 155. EUROPE BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 156. EUROPE BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 157. EUROPE BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 158. EUROPE BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 159. EUROPE BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 160. EUROPE BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 161. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 164. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 165. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 166. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 167. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 168. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 169. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 170. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 171. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 172. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 173. AFRICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. AFRICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. AFRICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 176. AFRICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 177. AFRICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 178. AFRICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 179. AFRICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 180. AFRICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 181. AFRICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 182. AFRICA BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 183. AFRICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 184. AFRICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 185. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 188. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 189. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 190. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 191. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 192. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 193. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 196. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL BUTORPHANOL MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL BUTORPHANOL MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. ASEAN BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. ASEAN BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. ASEAN BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 202. ASEAN BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 203. ASEAN BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 204. ASEAN BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 205. ASEAN BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 206. ASEAN BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 207. ASEAN BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. ASEAN BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. ASEAN BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 210. ASEAN BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 211. GCC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. GCC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. GCC BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 214. GCC BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 215. GCC BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 216. GCC BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 217. GCC BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 218. GCC BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 219. GCC BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 220. GCC BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 221. GCC BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 222. GCC BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 223. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 226. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 227. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 228. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 229. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 230. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 231. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 232. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 233. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 234. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 235. BRICS BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. BRICS BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. BRICS BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 238. BRICS BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 239. BRICS BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 240. BRICS BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 241. BRICS BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 242. BRICS BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 243. BRICS BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 244. BRICS BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 245. BRICS BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 246. BRICS BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 247. G7 BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. G7 BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. G7 BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 250. G7 BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 251. G7 BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 252. G7 BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 253. G7 BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 254. G7 BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 255. G7 BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 256. G7 BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 257. G7 BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 258. G7 BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 259. NATO BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. NATO BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. NATO BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 262. NATO BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 263. NATO BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 264. NATO BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 265. NATO BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 266. NATO BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 267. NATO BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 268. NATO BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 269. NATO BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 270. NATO BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. UNITED STATES BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 274. UNITED STATES BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 275. UNITED STATES BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 276. UNITED STATES BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 277. UNITED STATES BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 278. UNITED STATES BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 279. UNITED STATES BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 280. UNITED STATES BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 281. UNITED STATES BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 282. UNITED STATES BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 283. CANADA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 284. CANADA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 285. CANADA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 286. CANADA BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 287. CANADA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 288. CANADA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 289. CANADA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 290. CANADA BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 291. CANADA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 292. CANADA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 293. MEXICO BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 294. MEXICO BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 295. MEXICO BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 296. MEXICO BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 297. MEXICO BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 298. MEXICO BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 299. MEXICO BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 300. MEXICO BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 301. MEXICO BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 302. MEXICO BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 303. BRAZIL BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 304. BRAZIL BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 305. BRAZIL BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 306. BRAZIL BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 307. BRAZIL BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 308. BRAZIL BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 309. BRAZIL BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 310. BRAZIL BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 311. BRAZIL BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 312. BRAZIL BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 313. UNITED KINGDOM BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 314. UNITED KINGDOM BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 315. UNITED KINGDOM BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 316. UNITED KINGDOM BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 317. UNITED KINGDOM BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 318. UNITED KINGDOM BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 319. UNITED KINGDOM BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 320. UNITED KINGDOM BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 321. UNITED KINGDOM BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 322. UNITED KINGDOM BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 323. GERMANY BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 324. GERMANY BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 325. GERMANY BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 326. GERMANY BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 327. GERMANY BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 328. GERMANY BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 329. GERMANY BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 330. GERMANY BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 331. GERMANY BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 332. GERMANY BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 333. FRANCE BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 334. FRANCE BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 335. FRANCE BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 336. FRANCE BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 337. FRANCE BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 338. FRANCE BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 339. FRANCE BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 340. FRANCE BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 341. FRANCE BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 342. FRANCE BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 343. RUSSIA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 344. RUSSIA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 345. RUSSIA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 346. RUSSIA BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 347. RUSSIA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 348. RUSSIA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 349. RUSSIA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 350. RUSSIA BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 351. RUSSIA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 352. RUSSIA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 353. ITALY BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 354. ITALY BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 355. ITALY BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
• TABLE 356. ITALY BUTORPHANOL MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
• TABLE 357. ITALY BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 358. ITALY BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 359. ITALY BUTORPHANOL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 360. ITALY BUTORPHANOL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 361. ITALY BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 362. ITALY BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 363. SPAIN BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 364. SPAIN BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)

TABLE 365.